Continuing use of this assay in clinical trials and biomarker validation studies, and with normative reference populations, is expected to help establish the utility of NfL in evidence-based decision-making in care of patients with MS and as a potential measure of neurodegeneration, which may accelerate development of treatments that slow disease progression in other diseases such as ALS. This evidence concerns the gene NEFL and myeloid sarcoma.